CHAMPIONS ONCOLOGY, INC. Operating Lease Liability
CHAMPIONS ONCOLOGY, INC. (CSBR) had Operating Lease Liability of $10.25 million as of 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-09-11
- 2026-07-31: Operating Lease, Liability $10.25M.
- 2026-04-30: Operating Lease, Liability $4.51M.
- 2026-01-31: Operating Lease, Liability $4.89M.
- 2025-10-31: Operating Lease, Liability $5.27M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-07-31 | $10.25M 10-Q · filed 2026-09-11 |
| 2026-04-30 | $4.51M 10-K · filed 2026-07-27 |
| 2026-01-31 | $4.89M 10-Q · filed 2026-03-12 |
| 2025-10-31 | $5.27M 10-Q · filed 2025-12-15 |
| 2025-07-31 | $5.75M 10-Q · filed 2025-09-15 |
| 2025-04-30 | $6.11M 10-K · filed 2025-07-23 |
| 2025-01-31 | $6.44M 10-Q · filed 2025-03-17 |
| 2024-10-31 | $6.78M 10-Q · filed 2024-12-16 |
| 2024-07-31 | $7.11M 10-Q · filed 2024-09-13 |
| 2024-04-30 | $7.43M 10-K · filed 2024-07-19 |
| 2024-01-31 | $7.74M 10-Q · filed 2024-03-15 |
| 2023-10-31 | $8.05M 10-Q · filed 2023-12-13 |
| 2023-07-31 | $8.35M 10-Q · filed 2023-09-13 |
| 2023-04-30 | $8.60M 10-K · filed 2023-07-24 |
| 2023-01-31 | $8.87M 10-Q · filed 2023-03-16 |
| 2022-10-31 | $8.96M 10-Q · filed 2022-12-13 |
| 2022-07-31 | $9.23M 10-Q · filed 2022-09-12 |
| 2022-04-30 | $9.47M 10-K · filed 2022-07-22 |
| 2021-04-01 | $3.30M 10-K · filed 2022-07-22 |
| 2019-05-01 | $4.10M 10-K · filed 2019-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |